Roche's virtual event on key data presented at the 2021 MDA Virtual Clinical & Scientific Conference
Roche has hosted a virtual event on Friday, 19th March 2021.
- Phase II/III SUNFISH part 2: 24-month efficacy and safety of risdiplam in patients with Type 2 or non-ambulant Type 3 spinal muscular atrophy
Paulo Fontoura, M.D. Ph.D., Global Head Neuroscience and Rare Diseases Clinical Development
- Roche Neuroscience and Rare Disease franchise update
Simona Skerjanec, Therapeutic Area Head Neuroscience and Rare Diseases, Global Product Strategy
Karl Mahler, Head of Investor Relations and Roche Group Planning
Please register to access the webcast*